Outlook: The fate of US pharmaceutical giants is as diverse as these companies – from established companies such as Pfizer, Merck and Lilly, who are working hard to revitalize their product development lines, to the fast-growing young biotech companies. In the latter category of companies, Gilead Science is the leader. In 2014, the company's hepatitis C treatment drug Sovaldi broke the record for the pharmaceutical industry: in the first year of its marketing, it generated about $10 billion in sales. M&A transaction in 2014: Merck acquired biotech companies Cubist and Idenix for a total investment of $13.4 billion; Botox producer Ail was acquired by Atlas, based in Dublin, for $66 billion, in 2014 The largest trading activity in the industry. Product Development Line: Merck and Bristol-Myers Squibb are racing to capture a market-leading position for a new class of anticancer drugs (PD-1 checkpoint inhibitors) that enhance the immune system's ability to attack tumors. Outlook: In the UK pharmaceutical industry, AstraZeneca has long been under the GSK. However, the pattern has changed a lot in recent years. AstraZeneca's product development line shows greater hope, while GSK is working to curb sales declines in its core business of respiratory therapy drugs (because these drugs face price pressures in the US market), while the company In China, the impact of the corruption scandal. 2014 M & A action: AstraZeneca fought off a hostile takeover plan up to $ 117 billion proposed by Pfizer; GSK and Novartis reached a $ 20 billion asset swap agreement to boost its vaccines and consumer healthcare business. Product development line: The reason why AstraZeneca is optimistic is mainly from an experimental anticancer drug named Medi4736, which is currently in the late stage of trial. The company predicts that the drug's annual sales peak can reach 6.5 billion. Dollar. Outlook: Novartis and Roche are located on both sides of the Rhine in Basel, and the two competing pharmaceutical tycoons perform best in the industry. Roche has been focusing on the two markets of oncology and diagnostics and has dominated both areas. Novartis is in a strong position in the fields of antineoplastics, cardiovascular therapy, ophthalmology and generics. M&A transaction in 2014: Roche agreed to acquire US biotech company InterMune for $8.3 billion, the main drug of which was used to treat previously unresolved lung disease. Novartis sold its smaller animal health division to Lilly, while its vaccine business was exchanged with GSK's antineoplastics business. Product development line: LCZ696, a heart treatment drug developed by Novartis, may become one of the best new drugs listed in 2015. Analysts predict that the drug's annual sales peak will be as high as 10 billion US dollars. Outlook: In the ranks of multinational pharmaceutical companies, Sanofi is the only representative of France, the company is in a turbulent era. The company's core business diabetes treatment drug market performance is sluggish. In addition, in October 2014, Christopher Viehbacher was dismissed from the CEO of Sanofi in October 2014 due to disagreement with Chairman Serge Weinberg. At present, Weinberg temporarily took over the position of Weibach. 2014 M&A transaction action: Sanofi has avoided the M&A frenzy, but accelerated the departure of Weibbach due to disputes with the company's board of directors on the sale of some old drugs. Product development line: New products will eventually enter the market to replace those that have lost patent protection, such as blood thinner Polivi and sleeping pills Ambien. Sanofi predicts that by 2020, the company will be in an "unprecedented" product launch period, with a total of 18 new drugs, including the first vaccine for dengue fever and a new drug for high cholesterol. Outlook: German pharmaceutical groups are sometimes overlooked because they form part of a broader industry group. However, Bayer and Merck are the two oldest pharmaceutical companies in the world and are still not to be ignored in the current pharmaceutical industry. Bayer is larger than Germany's Merck, which has invested heavily in emerging markets and is in the top four positions in the Chinese market. Bayer's vast healthcare business includes the production of blood glucose meters, animal health products and more. 2014 M&A Transaction: Bayer plans to divest the plastics business and focus on healthcare and crop science. It acquired Merck's consumer business for $14.2 billion. Merck of Germany acquired Sigma-Aldrich, a US specialty chemicals company, for $17 billion. Product development line: Bayer currently has 18 drugs in the late stage of testing, but since 2003, Merck has not launched an important drug, the company is still working hard to revitalize its product development line. Feeding Tube Backpack,Kangaroo Feeding Bags,Kangaroo Pump Bags,Feeding Tube Bags K-MED Co., Ltd. , https://www.kmedasia.com